News

In the February edition of Dermatology Month in Review, new acne guidelines released by AAD, an FDA decision on nemolizumab, and an interview on potentially the first oral IL-23 inhibitor for psoriasis were among the major stories.

The newest version of ChatGPT accurately responded to most multiple-choice questions on ophthalmic cases but performed better on non-image–based questions.

The approval of the AGENT Drug-Coated Balloon is based on the AGENT IDE trial and was announced by Boston Scientific on March 01, 2024.

Older adults who are ≥ 90 years old, have dementia, are frail, and are undergoing vascular surgery have greater hospital readmission rates within 180 days.

Jairath discusses disease clearance and optimal treatment targeting in UC, highlighting what the ongoing VERDICT trial hopes to add to our understanding of improving patient outcomes.

These findings suggest much lower prices can be achieved for medications, with better alignment to the benefits of different biological psoriasis treatments.

A new study found menopausal hormone therapy was associated with a significant reduction in depressive symptoms over time with a greater reduction combined with antidepressants.

Results showed 95.8% of patients who were treated for HCV with DAA therapy and underwent renal transplantation did not experience HCV recurrence.

In the final part of our 3-part series, our panel of experts discuss what their fields and its leaders could do to make sure this lack of diversity in trials does not continue. These responses are highlighted in the following video and transcribed below.

In part 2 of our 3-part series on the impact of clinical trials lacking diversity, we are spotlighting responses to our second question, which addresses how the previously established lack of diversity in clinical trials has had a direct effect on the development and application of new therapies or devices in real-world settings.

In part 1 of our 3-part series on the impact of clinical trials lacking diversity, we are spotlighting responses to our first question, which sought to encapsulate the perspectives of our group of experts on how a historic lack of diversity in clinical trials has manifested itself in today’s care of patients from diverse backgrounds.

This article serves as a landing page for our 3-part series spotlighting how a lack of diversity in clinical trials has had a deleterious downstream effect on real-world care for people of color in the US, with perspective from experts across more than half a dozen specialties.

A progressive and significant increase in the frequency of strong opioid consumers was observed over a 12-year period, increasing from 5.8% to 12.8%.

The latest episode of New Insight with Veeral Sheth, MD features a conversation with Brad Doerschuk, the CEO of InFocus Clinical Research, on the important role of contract research organizations in ophthalmology research.

At week 24, patients with moderate to severe PsA receiving risankizumab had a significantly higher ACR20 response rate when compared with placebo.

People experiencing homelessness exhibit similar rates of morbidity compared with housed patients, but a longer adjusted length of hospital stay.

In honor of Rare Disease Day, this exploration of prurigo nodularis highlights the skin disease’s psychosocial impact on patients around the world living with the condition.

Cancer patients with behavioral health disorders, such as substance abuse, eating disorders, and sleep disorders have a 7.76% increase in health care costs, a new study found.

Positive topline results show apraglutide outperformed placebo for relative change from baseline in actual weekly parenteral support volume at week 24 in adults with SBS-IF.

This analysis presented at AAAAI suggests that the experimental OMIT delivery of allergens via toothpaste may allow for a safer alternative to other immunotherapies.

A new study found only 15% of people sleep the recommended 7 – 9 hours for ≥ 5 nights per week.

Our February 2024 month in review highlights EoE pipeline news, new FMT guidelines, and research about endoscopic inflammation and disease activity in IBD.

A study from Brigham and Women's Hospital has identified 6 blood-based biomarkers that may predict cardiovascular disease risk in rheumatoid arthritis patients.

Hosts breakdown a pair of recent publications related to better understanding the strengths and limitations of MARD as well as a study comparing the Dexcom G7 and FreeStyle Libre 3 sensors.

No statistically significant differences in the odds of remission at ≤12 months were observed between patients receiving adalimumab compared with other biologics.

In an analysis of the DISCOVER-2 trial, guselkumab treatment reduced impairment in work productivity and improved general health status in PsA over 2 years.

Patients perceived WelTel as a beneficial tool for providing quality care across domains including efficiency, safety, and patient-centeredness.

Headache prevalence was significantly higher in the PsA and axSpA cohorts compared with healthy controls.

This announcement by UCB follows the results of four phase 3 studies on the use of bimekizumab for PsA, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.

Inflammatory markers, infliximab levels, and physician global assessment scores remained similar when assessed pre- and post-switch to an infliximab biosimilar.